Next 10 |
REDWOOD CITY, Calif., July 18, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the second quarter of 2024 on Thursday, August 8, 2024, following the close of market. Codexis management will ...
2024-07-01 17:28:05 ET More on Codexis Codexis, Inc. (CDXS) Q1 2024 Earnings Call Transcript Codexis, Inc. 2024 Q1 - Results - Earnings Call Presentation Codexis GAAP EPS of -$0.16 beats by $0.02, revenue of $17.1M beats by $3.8M Codexis Q1 2024 Earnings Prev...
REDWOOD CITY, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into an asset purchase agreement with Crosswalk Therapeutics for the Company’s investigational Fabry and Pompe disease compounds. Under...
2024-05-30 17:10:08 ET Gainers: Zscaler ( ZS ) +15% . Ambarella ( AMBA ) +14% . OmniAb ( OABI ) +4% . Intellia Therapeutics ( NTLA ) +4% . Summit Therapeutics ( SMMT ) +3% . Losers: MongoDB ( MDB ) -22% . ...
2024-05-30 07:30:04 ET Cantor Fitzgerald analyst issues OVERWEIGHT recommendation for CDXS on May 30, 2024 06:15AM ET. CDXS was trading at $3.19 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 2 - Buy rec...
2024-05-30 07:00:11 ET Kristen Kluska from Cantor Fitzgerald issued a price target of $11.00 for CDXS on 2024-05-30 06:15:00. The adjusted price target was set to $11.00. At the time of the announcement, CDXS was trading at $3.19. CDXS currently trades -34.90% versus its...
REDWOOD CITY, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will attend the Jefferies Global Healthcare Conference, being held June 5-6, 2024, in New York, New York. Management will participate in a f...
REDWOOD CITY, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will participate in a panel discussion titled, “Sustainable API Manufacturing” at the TD Cowen 2 nd Annual Sustainability Week, ...
REDWOOD CITY, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has successfully synthesized an oligonucleotide via an enzymatic route to support RNA-based therapeutics manufacturing. Data highlighting this historic man...
2024-05-02 20:24:08 ET Codexis, Inc. (CDXS) Q1 2024 Earnings Conference Call May 02, 2024 04:30 PM ET Company Participants Carrie McKim - Director, Investor Relations Stephen Dilly - President & Chief Executive Officer Stefan Lutz - Senior Vice President, Res...
News, Short Squeeze, Breakout and More Instantly...
REDWOOD CITY, Calif., July 18, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the second quarter of 2024 on Thursday, August 8, 2024, following the close of market. Codexis management will ...
REDWOOD CITY, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into an asset purchase agreement with Crosswalk Therapeutics for the Company’s investigational Fabry and Pompe disease compounds. Under...
2024-05-30 07:30:04 ET Cantor Fitzgerald analyst issues OVERWEIGHT recommendation for CDXS on May 30, 2024 06:15AM ET. CDXS was trading at $3.19 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 2 - Buy rec...